Statera Biopharma, Inc. STAB
OTC PK
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Net Income | -- | -- | -- | -101.85M | -28.84M |
| Total Depreciation and Amortization | -- | -- | -- | 255.60K | 143.20K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | -- | 71.92M | 13.19M |
| Change in Net Operating Assets | -- | -- | -- | 1.49M | -2.04M |
| Cash from Operations | -- | -- | -- | -28.19M | -17.55M |
| Capital Expenditure | -- | -- | -- | -183.00K | -89.10K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 13.65M | 13.65M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | 13.46M | 13.56M |
| Total Debt Issued | -- | -- | -- | 14.87M | 14.77M |
| Total Debt Repaid | -- | -- | -- | -897.70K | -97.70K |
| Issuance of Common Stock | -- | -- | -- | 7.34M | 6.45M |
| Repurchase of Common Stock | -- | -- | -- | -- | -4.50M |
| Issuance of Preferred Stock | -- | -- | -- | 5.69M | 7.34M |
| Repurchase of Preferred Stock | -- | -- | -- | -5.69M | -5.69M |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -329.30K | -390.90K |
| Cash from Financing | -- | -- | -- | 20.99M | 17.89M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -6.70K | -2.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -- | -- | 6.25M | 13.90M |